高血症:药物治疗和临床考虑
Evan S Sinnathamby1, Kelly T Banh1, William T Barham1
1Medicine, Louisiana State University Health Sciences Center, New Orleans, USA.
Cureus
|February 26, 2024
概括
过高血症是一种严重的疾病,含量很高,可以用新的胃肠道药物来治疗. 这项研究审查了聚二硫酸盐,环酸盐和帕蒂罗默,以有效减少.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血症,定义为血清>5.5 mmol/l,存在风险,包括致命的心律失常和肌肉功能障碍.
- 慢性病 (CKD) 和糖尿病等疾病是高胆血症的常见原因.
- 诊断依赖于临床表现,心电图 (ECG) 发现和实验室水平.
研究的目的:
- 评估新兴胃肠道 (GI) 药物在治疗高血症方面的疗效和特征.
- 为了比较聚二硫酸盐 (SPS),环环酸盐 (SZC) 和帕特罗默的益处和禁忌.
- 为临床医生提供有关降低血清的可用药理选择的信息.
主要方法:
- 综述关于高胆血症管理的现有文献.
- 对SPS,SZC和patiomer的作用机制的分析.
- 药物选择性,胃肠道主要作用和临床特征的比较.
主要成果:
- SPS,SZC和patiomer是具有增加选择性的胃肠道作用剂.
- 每种药物都有其独特的优势和潜在的禁忌.
- 这些药物提供了超越传统急性治疗方法 (如葡萄糖/胰岛素和透析) 的额外治疗选择.
结论:
- 较新的胃肠道选择性药物 (SPS,SZC,patiomer) 为管理高血症提供了有价值的工具.
- 了解这些药物的独特特征对于有效的患者护理至关重要.
- 临床医生在制定高血症治疗策略时应该了解这些药物.
相关概念视频
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
554
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
554
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
996
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
996
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
744
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
744
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431